Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 1.01, 7.01, 9.01 · 8-K

Twist Bioscience Corporation

TWSTNASDAQEQUITYCurrent

Entry into a Material Definitive Agreement · Regulation FD Disclosure

Item 1.01 Entry into a Material Definitive Agreement. On August 4, 2026, Twist Bioscience Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co.…

Filed Aug 5, 2026Accepted Aug 5, 2026, 5:27 PM EDTCIK 1581280Accession 0001104659-26-091280
Share

Company context

At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal - more experiments, more iterations, more chances for remarkable discoveries.

Current securities

Recent company filings

  1. Results of Operations and Financial ConditionNov 12, 2026
  2. SCHEDULE 13G/A - filed by Artisan Partners Limited Partnership regarding Twist Bioscience CorpNov 12, 2026
  3. SCHEDULE 13G - filed by STATE STREET CORP regarding Twist Bioscience CorpNov 10, 2026
  4. SCHEDULE 13G/A - filed by FMR LLC regarding Twist Bioscience CorpNov 5, 2026
  5. 144 filingSep 21, 2026

Registered securities in this filing

Twist Bioscience Corporation · 8-K · Filed 2026-08-05

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol
TWST
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-08-04

Dimensions: Not supplied

Accession 000110465926091280 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 1.01, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement. On August 4, 2026, Twist Bioscience Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, William Blair & Company, L.L.C., Leerink Partners LLC, and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell 3,125,000 shares of its common stock to the Underwriters (the “Offering”). The Shares will be sold to the Underwriters at a public offering price of $96.00 per share, less the underwriting discount and commissions. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 468,750 shares of its common stock. On August 5, 2026, the Underwriters exercised their option to purchase all 468,750 additional shares of common stock (the “Option Shares”) at a price per share of $96.00, less the underwriting discount and commissions. The net proceeds to the Company from the Offering, including from the exercise of the Underwriters’ option to purchase the Option Shares in full, are expected to be approximately $327.1 million, after deducting underwriting discounts and commissions and estimated Offering expenses payable by the Company. The Offering is expected to close on or about August 6, 2026, subject to customary closing conditions. The Offering is being made pursuant to the Company’s automatic shelf registration statement on Form S-3 (No. 333-296897) and the base prospectus included therein (the “Registration Statement”), which was filed with the Securities and Exchange Commission (the “SEC”) on June 18, 2026, and became automatically effective upon filing, the preliminary prospectus supplement, dated August 4, 2026, filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the “Securities Act”), and the final prospectus supplement, dated August 4, 2026, filed with the SEC pursuant to Rule 424(b)(5) of the Securities Act. The Underwriting Agreement contains customary representations and warranties, conditions to closing, market standoff provisions, termination provisions and indemnification obligations, including for liabilities under the Securities Act. The Underwriting Agreement is attached hereto as an exhibit to provide interested persons with information regarding its terms, but is not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of the Underwriting Agreement as of specific dates indicated therein, were solely for the benefit of the parties to the Underwriting Agreement, and may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Underwriting Agreement. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement. A copy of the Underwriting Agreement is filed with this Current Report on Form 8-K as Exhibit 1.1 and is incorporated herein by reference. A copy of the opinion and consent of Orrick, Herrington & Sutcliffe LLP relating to the validity of the shares issued in connection with the Offering is filed herewith as Exhibit 5.1 and Exhibit 23.1, respectively.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 4, 2026, the Company issued a press release to announce a proposed offering of $250.0 million of shares pursuant to the Registration Statement (the “Offering Press Release”). A copy of the Offering Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. On August 4, 2026, the Company also issued a press release to announce that it had priced an upsized $300.0 million offering (the “Pricing Press Release”). A copy of the Pricing Press Release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Filed exhibits (2)
EX-99.1 (by filename) tm2622018d2_ex99-1.htm

EX-99.1 4 tm2622018d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock SOUTH SAN FRANCISCO, Calif. - August 4, 2026 - Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock to be sold in the proposed offering are being offered by Twist. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Twist intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and marketable securities, to fund research and development investments, expansion of manufacturing capacity, product offerings and the remainder for working capital and other general corporate purposes. Gol…

Open exhibit ↗
EX-99.2 (by filename) tm2622018d2_ex99-2.htm

EX-99.2 5 tm2622018d2_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif. - August 4, 2026 - Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Twist. The gross proceeds to Twist from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $300.0 million. In addition, Twist has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on August 6, 2026, subject to the satisfaction of customary closing conditions. Twist intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to fund research and dev…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.